Funds
WisdomTree this week launched a further two UCITS ETFs listed on the London Stock Exchange. This brings the total to six ETFs listed on the LSE in the past four weeks and further solidifies its position as a pioneer of dividend-weighted ETFs.
The two latest ETFs are:
WisdomTree Emerging Markets Equity Income UCITS ETF (DEM)
WisdomTree Emerging Markets SmallCap Dividend UCITS ETF (DGSE)
As with the first four WisdomTree ETFs listed on 24 October 2014, the ETFs are Irish-domiciled and physically replicated, with underlying shares held with State Street, a global leading custodian and administrator. One of the world’s leading
The SS&C GlobeOp Forward Redemption Indicator for November 2014 measured 5.05%, up from 3.12% in October.
The SS&C GlobeOp Forward Redemption Indicator represents the sum of forward redemption notices received from investors in hedge funds administered by SS&C GlobeOp on the SS&C GlobeOp platform, divided by the AuA at the beginning of the month for SS&C GlobeOp fund administration clients on the SS&C GlobeOp platform. Forward redemptions as a percentage of SS&C GlobeOp's assets under administration on the SS&C GlobeOp platform have trended significantly lower since reaching a high of 19.27% in November 2008. The next publication date is 19
The Securities and Exchange Commission has suspended trading in four companies that claim to be developing products or services in response to the Ebola outbreak, citing a lack of publicly available information.
The SEC simultaneously issued an investor alert warning about the potential for fraud in microcap companies purportedly involved in Ebola prevention, testing, or treatment, noting that scam artists often exploit the latest crisis in the news cycle to lure investors into supposedly promising investment opportunities.
The SEC Enforcement Division and its Microcap Fraud Task Force work to proactively identify microcap companies that are publicly disseminating information that appears
Senrigan Capital Group Ltd, the Asia event-driven hedge fund backed by Blackstone Group LP, returned 15 per cent in the first 10 months of this year, reports Bloomberg.
The USD348 million Senrigan Master Fund gained 6.4 per cent in September and 1.4 per cent in October, said people with knowledge of the matter
.
Senrigan is headed for the best year since its November 2009 inception. Event-driven hedge funds globally had the worst two months in September and October since May 2012, according to an index compiled by Hedge Fund Research Inc, as US managers have been hit by the unraveling of deals involving
Market sentiment has been shaken recently over fears of low growth in the Eurozone and a potential slide back into recession. The German government downgraded its economic forecast to 1.2 per cent for 2014; and this is meant to be the Eurozone’s powerhouse economy.
Nevertheless, pockets of growth are emerging for investors to exploit. “We are seeing an uptick in domestic real estate activity in Dublin. It has really picked up in the last year. International managers are looking to buy in to the recovery in Ireland and a number of them are choosing to do it through regulated fund
Investor redemptions from hedge funds in October outpaced new allocations for the second consecutive month resulting in a slight net outflow of USD2.9 billion (only 0.10% of AUM), according to eVestment.
The industry has not had two consecutive months of outflow since the wake of the 2012 edition of the European sovereign crisis.
Investor sentiment towards equity-focused hedge funds was negative for the second consecutive month October, confirming a deviation from the positive trend which had been in place the preceding 14 months. October redemptions appear more related to elevated losses in June and July, rather than due to
Although much maligned for sub-par performance since the dot-com crash, venture capital returns for more recent funds have picked up significantly – one-year horizon returns are among the best in the entire private equity industry. Preqin’s latest special report examines the drivers of this recent success, and uncovers the impact of improved performance on LP attitudes towards the asset class and the prospects for future fundraising.
Following a rapid reversal of fortunes at the turn of the millennium, the venture capital industry has experienced largely lacklustre returns which have led to tough fundraising conditions for all but a select group
Columbia Management and Blackstone Alternative Asset Management (BAAM) are to research and develop investment solutions that leverage Columbia’s asset management capabilities and Blackstone’s hedge fund solutions business.
Columbia has considerable experience in asset allocation and alternative investing, with Jeff Knight, Global Head of Investment Solutions and Asset Allocation, and William Landes, PhD, Deputy Head of Global Investment Solutions, leading the company’s efforts to develop and manage compelling products and solutions for its clients.
Columbia’s expertise in asset allocation, equity and fixed-income investment management, and sub-advisory selection capabilities offers investors a powerful opportunity to help meet their specific needs. The addition
The Credit Suisse Hedge Fund Index finished down 0.80% for the month of October with seven of the ten sub strategies ending the month in negative territory.
Managed Futures, Equity Market Neutral and Long/Short Equity were the positive performers recording returns of 1.81%, 0.45% and 0.01% respectively.
The month’s biggest loser was Dedicated Short Bias which finished the month down 3/99%.
Actavis is to acquire pharmaceutical company Allergan for a combination of USD129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock.
Based on the closing price of Actavis shares on 14 November, 2014, the transaction is valued at approximately USD66 billion, or USD219 per Allergan share. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than USD23 billion anticipated in 2015. The transaction has been unanimously approved by the Boards of Directors of Actavis and Allergan, and is supported by the
